Patents by Inventor Robert S. Ames
Robert S. Ames has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7982005Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: GrantFiled: March 1, 2010Date of Patent: July 19, 2011Assignee: GlaxoSmithKline LLCInventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Publication number: 20100316634Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: ApplicationFiled: March 1, 2010Publication date: December 16, 2010Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Publication number: 20090017020Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: ApplicationFiled: June 6, 2008Publication date: January 15, 2009Inventors: Robert S. AMES, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Patent number: 7399837Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: GrantFiled: October 20, 2005Date of Patent: July 15, 2008Assignees: SmithKline Beecham Corporation, SmithKline Beecham P.L.C.Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Patent number: 6946130Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: GrantFiled: November 4, 2003Date of Patent: September 20, 2005Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Patent number: 6881827Abstract: AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.Type: GrantFiled: August 9, 2002Date of Patent: April 19, 2005Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Nabil Elshourbagy, Usman Shabon, Robert S. Ames, Henry S. Sarau, Lisa Vawter, David Michalovich
-
Publication number: 20040156850Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: ApplicationFiled: November 4, 2003Publication date: August 12, 2004Applicants: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Publication number: 20030059856Abstract: Disclosed are methods for discovering agonists and antagonists of the interaction between monkey AXOR8, human AXOR8, and human AXOR52 receptors with their natural ligands: human BV8-a, mouse BV8-a, frog BV8, human BV8-b, human PRO1186, human PRO1186 variant, and mamba intestinal toxin (herein “MIT”).Type: ApplicationFiled: April 25, 2002Publication date: March 27, 2003Inventors: Robert S. Ames, Henry M. Sarau, J. Randall Slemmon, Dean E. McNulty, Lisa Vawter, James J. Foley
-
Publication number: 20030059429Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: ApplicationFiled: May 13, 2002Publication date: March 27, 2003Applicant: SmithKline Beecham CorporationInventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Patent number: 6506878Abstract: HMTMF81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HMTMF81 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: June 5, 2000Date of Patent: January 14, 2003Assignee: Smithkline Beecham CorporationInventors: Catherine E. Ellis, Wendy Halsey, Ganesh M. Sathe, Robert S. Ames, James J. Foley, Henry M. Sarau, Jon Chambers
-
Patent number: 6461836Abstract: AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.Type: GrantFiled: April 10, 2000Date of Patent: October 8, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Nabil Elshourbagy, Usman Shabon, Robert S. Ames, Henry S. Sarau, Lisa Vawter, David Michalovich
-
Patent number: 6433156Abstract: Rabbit G alpha 16 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing rabbit G alpha 16 polypeptides and polynucleotides in screening of antagonists or agonists of cells co-expressing a G-protein coupled receptor and rabbit G alpha 16.Type: GrantFiled: December 22, 1998Date of Patent: August 13, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham plcInventors: Robert S. Ames, John A. Feild, Tania Testa
-
Publication number: 20020038007Abstract: Human 11cb splice variant polypeptides and DNA (RNA) encoding such an 11cb splice variant and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such an 11cb splice variant for the treatment of to treat infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome; among others,.Type: ApplicationFiled: August 9, 2001Publication date: March 28, 2002Inventors: Robert S. Ames, Henry M. Sarau, James J. Foley, Derk J. Bergsma, Catherine E. Ellis, Jon K. Chambers
-
Publication number: 20020026042Abstract: Rabbit G alpha 16 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed.Type: ApplicationFiled: September 12, 2001Publication date: February 28, 2002Inventors: Robert S. Ames, John A. Feild, Tania Testa
-
Patent number: 6344342Abstract: HOFNH30 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HOFNH30 polypeptides and polynucleotides in terapy, and diagnostic assays for such.Type: GrantFiled: April 18, 2001Date of Patent: February 5, 2002Assignee: SmithKline Beecham CorporationInventors: Ping Tsui, Catherine E. Ellis, Ganesh M. Sathe, Stephanie Van Horn, Robert S. Ames, James J. Foley, Laura R. Fitzgerald, Henry M. Sarau, Jonathan K. Chambers
-
Patent number: 6242572Abstract: HOFNH30 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HOFNH30 polypeptides and polynucleotides in terapy, and diagnostic assays for such.Type: GrantFiled: June 4, 1999Date of Patent: June 5, 2001Assignee: SmithKline Beecham CorporationInventors: Ping Tsui, Catherine E. Ellis, Ganesh M. Sathe, Stephanie Van Horn, Robert S. Ames, James J. Foley, Laura R. Fitzgerald, Henry M. Sarau, Jonathan K. Chambers
-
Patent number: 6238873Abstract: Disclosed are methods for discovering agonists and antagonists of the interaction between UDP-glucose, UDP-galactose, UDP-glucuronic acid, UDP-N-acetyl glucosamine, as well as related UDP sugars, and their cellular receptor, human KIAA0001, which may have utility in the treatment of several human diseases and disorders, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; restenosis; atherosclerosis; diseases characterized by excessive smooth muscle cell proliferation; aneurysms; wound healing; diseases characterized by loss of smooth muscle cells or reduced smooth muscle cell proliferation; stroke; ischemia; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurologicType: GrantFiled: April 30, 1999Date of Patent: May 29, 2001Assignee: Smithkline Beecham CorporationInventors: Robert S. Ames, Anne Romanic Arnold, Jonathan K. Chambers, James Joseph Foley, Henry M. Sarau, Brian R. Stewart
-
Patent number: 6200775Abstract: HMTMF81 polypeptides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HMTMF81 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris, myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: March 19, 1998Date of Patent: March 13, 2001Assignee: SmithKline Beecham CorporationInventors: Catherine E. Ellis, Wendy Halsey, Ganesh M. Sathe, Robert S. Ames, James J. Foley, Henry M. Sarau, Jon Chambers
-
Patent number: 6129913Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: GrantFiled: June 19, 1997Date of Patent: October 10, 2000Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Patent number: 5190462Abstract: An N.times.M electrical connector suitable for use at microwave frequencies comprises a first set of N insulating parallel substrates each containing M notches with adjacent planar conductors and a second set of M parallel substrates having up to N spaced-apart conductors, wherein the notch-to-notch and conductor-to-conductor spacing of the first set matches the substrate-to-substrate spacing of the second set and vice versa, so that when the second set is pushed into the notches of the first set, each notch and associated conductor on the first set aligns with related conductors on the second set of "L" shaped relation. One or more spring contacts at each intersection provide positive electrical connection between the proximate conductors. The arrangement is especially useful for microwave systems since multiple signal lines and ground planes may be connected simultaneously without interference or substantial electrical discontinuity.Type: GrantFiled: September 3, 1991Date of Patent: March 2, 1993Assignee: Motorola, Inc.Inventors: John K. Lauchner, Andrew J. Schlaiss, Robert S. Ames